There was an increase in use of neuraxial anesthesia and peripheral nerve block analgesia rather than general anesthesia for hip fracture procedures.

Ustekinumab is associated with a higher rate of clinical remission at 6 months compared with anti-TNF therapy among patients with CLDP. Ustekinumab may be more effective than anti-tumor necrosis ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.